Crossmark

Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit

Crossref DOI link: https://doi.org/10.1007/s10120-021-01225-1

Published Online: 2021-08-07

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kalff, Marianne C. https://orcid.org/0000-0003-4821-2806
Wagner, Anna D.

Verhoeven, Rob H. A.

Lemmens, Valery E. P. P.

van Laarhoven, Hanneke W. M.

Gisbertz, Suzanne S.

van Berge Henegouwen, Mark I.

,
License Information

Text and Data Mining valid from 2021-08-07

Version of Record valid from 2021-08-07
More Information

Article History

Received: 18 January 2021

Accepted: 27 July 2021

First Online: 7 August 2021

Declarations

:

: Wagner has received consulting fees from BMS, Servier Suisse, Merck, MSD, Bayer, EMD Serono, Lilly, Celgene, Shire, and Pfizer, non-financial support (for congress participations) from Sanofi, Astra-Zeneca, AbbVIE, and Ipsen, and an educational grant from Roche to EORTC. Verhoeven has received unrestricted research grants from BMS and Roche. Van Laarhoven has served as a consultant for BMS, Celgene, Lilly, Merck, Nordic, and Servier, and has received unrestricted research funding from Bayer, BMS, Celgene, Lilly, Merck Serono, MSD, Nordic, Philips, Roche, and Servier. Van Berge Henegouwen reports research grants from Olympus and Stryker, in addition to consulting fees from Medtronic, Mylan, and Johnson and Johnson. Lemmens has received unrestricted research grants and educational grants from Roche. The remaining authors have no conflict of interest to report.

Document is current

Any future updates will be listed below